Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
International Journal of Radiation Oncology*Biology*Physics. 2004;58(2):344-352 
554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cells
European Journal of Cancer Supplements. 2006;4(12):168
194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer
Molecular Therapy. 2012;20:S77
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts
Cancer Chemotherapy and Pharmacology. 2007;61(2):179-188
Dual HER-2/EGFR tyrosine kinase inhibitors
Breast Cancer Research. 2001;3(1):
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor
Clinical Breast Cancer. 2016;16(5):344-348
Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates
Breast Cancer Research. 2000;2(3):
Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer
Breast Cancer Research. 2009;11(S1):
567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
European Journal of Cancer Supplements. 2006;4(12):172
Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts
European Journal of Cancer. 2002;38:S62